Selma Sahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selma Sahin has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Sinan Kaynak
Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey
7 shared publications - Levent Öner
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara 06230, Turkey
5 shared publications - Mustafa Çelebier
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara 06230, Türkiye
5 shared publications - Nihan Izat
Centre for Applied Pharmacokinetic Research, The University of Manchester Manchester UK
5 shared publications - Fatima Khalifa Al-Sulaiti
Faculty of Pharmacy, Pharmaceutical Technology Department Hacettepe University Ankara Türkiye
4 shared publications - Tugba Gulsun
Hacettepe Üniversitesi
4 shared publications
Latest Publications
- 2 December 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32 (22) , 1740-1748
Multi-Segmental Evaluation of Intestinal Permeability of Amlodipine at Two Dose Levels
Background: Intestinal permeability plays a crucial role in drug absorption, as it varies across different gastrointestinal regions, affecting the bioavailability of orally administered drugs. This variability, combined with dose-dependent absorption, influences the overall efficacy and pharmacokinetics of the drug. Objective: This study aimed to investigate the impact of three intestinal regions (jejunum, ileum, and colon) along with two different doses of amlodipine (AML) (5 mg and 10 mg) on its permeability. Methods: An optimized HPLC method was developed and validated for the simultaneous quantification of AML, metoprolol (MTP), and phenol red (PR), while a modified single-pass intestinal perfusion (SPIP) was used to assess AML permeability across different intestinal segments. Results: Net Water Flux (NWF) showed significant fluctuations, with high positive values in the colon, indicating distinct physiological responses in this region. The effective permeability (Peff) of AML varied across different intestinal segments and doses. In the jejunum and ileum, the Peff of AML decreased with increasing doses from 5 mg to 10 mg, while in the colon, Peff remained relatively stable. Peff values ranged from 3.50 × 10−4 cm/s for the 5 mg dose to 1.80 × 10−4 cm/s for the 10 mg dose in the jejunum, from 3.30 × 10−4 cm/s (5 mg) to 2.41 × 10−4 cm/s (10 mg) in the ileum, and from 6.65 × 10−4 cm/s (5 mg) to 6.79 × 10−4 cm/s (10 mg) in the colon. Conclusion: This study demonstrated significant segmental and dose-dependent variations in the intestinal permeability of AML using the SPIP model in rats.
- 2 December 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32 (22) , 1740-1748
Multi-Segmental Evaluation of Intestinal Permeability of Amlodipine at Two Dose Levels
Background: Intestinal permeability plays a crucial role in drug absorption, as it varies across different gastrointestinal regions, affecting the bioavailability of orally administered drugs. This variability, combined with dose-dependent absorption, influences the overall efficacy and pharmacokinetics of the drug. Objective: This study aimed to investigate the impact of three intestinal regions (jejunum, ileum, and colon) along with two different doses of amlodipine (AML) (5 mg and 10 mg) on its permeability. Methods: An optimized HPLC method was developed and validated for the simultaneous quantification of AML, metoprolol (MTP), and phenol red (PR), while a modified single-pass intestinal perfusion (SPIP) was used to assess AML permeability across different intestinal segments. Results: Net Water Flux (NWF) showed significant fluctuations, with high positive values in the colon, indicating distinct physiological responses in this region. The effective permeability (Peff) of AML varied across different intestinal segments and doses. In the jejunum and ileum, the Peff of AML decreased with increasing doses from 5 mg to 10 mg, while in the colon, Peff remained relatively stable. Peff values ranged from 3.50 × 10−4 cm/s for the 5 mg dose to 1.80 × 10−4 cm/s for the 10 mg dose in the jejunum, from 3.30 × 10−4 cm/s (5 mg) to 2.41 × 10−4 cm/s (10 mg) in the ileum, and from 6.65 × 10−4 cm/s (5 mg) to 6.79 × 10−4 cm/s (10 mg) in the colon. Conclusion: This study demonstrated significant segmental and dose-dependent variations in the intestinal permeability of AML using the SPIP model in rats.
- 19 November 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (2) , 104064
Assessment of intranasal permeability and pharmacological activity of glyburide-loaded nanosuspension formulation for Alzheimer’s disease
- 19 November 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (2) , 104064
Assessment of intranasal permeability and pharmacological activity of glyburide-loaded nanosuspension formulation for Alzheimer’s disease
- 8 October 2025
- Published by Wiley in Biomedical Chromatography
- Vol. 39 (11) , e70229
An Isocratic RP‐HPLC Method for Simultaneous Quantification of Nateglinide and Furosemide: Application to In Vitro Caco‐2 Intestinal Permeability Studies of Nanodrugs
In the booming era of nanomedicines, Caco‐2 intestinal permeability experimental models allow characterizing intestinal permeabilities of nanopharmaceuticals and are conducted in the presence of cell culture media (CCM) and stabilizers. Methods for simultaneous quantification of furosemide (FRS) and nateglinide (NTG) in Caco‐2 experiments are lacking. We developed and validated a novel, simple, and practical reversed‐phase high‐performance liquid chromatography (RP‐HPLC) method with UV detection to simultaneously quantify FRS and NTG in the presence of CCM and stabilizers (Povidone K‐25, Pluronic F‐38) for Caco‐2 intestinal permeability experiments exploring nanoformulations. FRS and NTG nanosuspensions were prepared using high‐speed ultrasonic homogenization top–down technique. Caco‐2 cell culture studies were conducted. ICH Q2(R1) guideline requirements (i.e., selectivity, specificity, accuracy, precision, robustness, stability) were met. System suitability and linearity (FRS: 5.12–40.00 μg/mL; NTG: 7.31–50.00 μg/mL), with high determination coefficients (>0.999), and short retention times (FRS: 3.3 min; NTG: 5.3 min) were achieved. NTG and FRS in Caco‐2 samples were successfully simultaneously quantified, proving usefulness for nanodrug research applications. Varying stabilizers impact intestinal permeability. This work simulates pragmatic conditions, as cardiovascular patients are co‐administered these drugs, paving the pathway to using our novel method for a wide range of “bench‐to‐bedside” nanomedicine research designs to tackle the challenges of polypharmacy in this complex population.
- 8 October 2025
- Published by Wiley in Biomedical Chromatography
- Vol. 39 (11) , e70229
An Isocratic RP‐HPLC Method for Simultaneous Quantification of Nateglinide and Furosemide: Application to In Vitro Caco‐2 Intestinal Permeability Studies of Nanodrugs
In the booming era of nanomedicines, Caco‐2 intestinal permeability experimental models allow characterizing intestinal permeabilities of nanopharmaceuticals and are conducted in the presence of cell culture media (CCM) and stabilizers. Methods for simultaneous quantification of furosemide (FRS) and nateglinide (NTG) in Caco‐2 experiments are lacking. We developed and validated a novel, simple, and practical reversed‐phase high‐performance liquid chromatography (RP‐HPLC) method with UV detection to simultaneously quantify FRS and NTG in the presence of CCM and stabilizers (Povidone K‐25, Pluronic F‐38) for Caco‐2 intestinal permeability experiments exploring nanoformulations. FRS and NTG nanosuspensions were prepared using high‐speed ultrasonic homogenization top–down technique. Caco‐2 cell culture studies were conducted. ICH Q2(R1) guideline requirements (i.e., selectivity, specificity, accuracy, precision, robustness, stability) were met. System suitability and linearity (FRS: 5.12–40.00 μg/mL; NTG: 7.31–50.00 μg/mL), with high determination coefficients (>0.999), and short retention times (FRS: 3.3 min; NTG: 5.3 min) were achieved. NTG and FRS in Caco‐2 samples were successfully simultaneously quantified, proving usefulness for nanodrug research applications. Varying stabilizers impact intestinal permeability. This work simulates pragmatic conditions, as cardiovascular patients are co‐administered these drugs, paving the pathway to using our novel method for a wide range of “bench‐to‐bedside” nanomedicine research designs to tackle the challenges of polypharmacy in this complex population.
- Open Access
- 7 August 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (9) , 1-28
Impact of Extracorporeal Membrane Oxygenation Life Support on Vancomycin Population Pharmacokinetics in Critical Illness: A Systematic Review
Background An extracorporeal membrane oxygenation (ECMO) device represents an additional functional body compartment, potentially impacting vancomycin pharmacokinetics. Objectives This systematic review aimed to: (1) provide a comprehensive summary of vancomycin population pharmacokinetics (Pop-PK) in critically ill patients receiving ECMO and; (2) associate the findings with clinical practices and dosing recommendations. Methods PubMed, Embase and Google Scholar databases were searched for vancomycin non-linear mixed-effects modelling Pop-PK studies in ECMO patients (inception-May 2024). Standardized, pre-tested and pilot-tested tools were used for quality assessment and data extraction utilizing triangulation. Summary measures included typical values for vancomycin pharmacokinetic parameters, influential covariates, and associated interindividual and residual variabilities. Results Seven studies reporting an approximate total of 1600 vancomycin blood concentrations (range: 33–433 concentrations per study) collected from 215 patients (range: 11–93 patients per study) were included. Pop-PK models fitted three-compartment (n = 1), two-compartment (n = 5), or one-compartment (n = 1) models. Various modalities [venovenous-ECMO (n = 6); venoarterial-ECMO (n = 5), centrifugal-pump (n = 6), roller pump (n = 1)] and age groups were reported [pediatrics (n = 2); adults (n = 6)]. Vancomycin clearance and central volume of distribution (V1) ranged between 0.0579–4.32 L/h and 0.13–3.32L/kg, respectively. Relatively high between-subject variability (BSV) exists (clearance: 0.1%–77%; V1: 0.33%–94.8%). Models failed to explain maximally 19.4% of the overall variations, successfully explaining at least 80.6% of the variabilities in vancomycin disposition in ECMO. Age and body weight were significant covariates on clearance and V1. Additionally, glomerular filtration rate, serum creatinine, creatinine clearance, and use of dialysis were significant covariates on clearance. Clinical status-related covariates (i.e., acute physiology and chronic health evaluation II (APACHE-2) score, sequential organ failure assessment (SOFA) score, presence of shock) and ECMO modality-related covariates (pump type/flow rate, ECMO mode) were not significant covariates in the final clearance and V1 models. Conclusion This work comprehensively compiles up-to-date population-approach-based dosing simulations and pharmacokinetic models of vancomycin in ECMO, with special focus on influential predictors of vancomycin disposition to guide clinical dosing decisions. Relatively small sample sizes of patients were reported, a limitation that needs to be addressed in future large-scale studies. Observed BSV mandates therapeutic drug monitoring using Pop-PK models and parameters summarized in this work. Large-scale studies are needed to explore unexplored covariates, resulting in more informative dosing nomograms.
- 7 August 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (9) , 1-28
Open AccessImpact of Extracorporeal Membrane Oxygenation Life Support on Vancomycin Population Pharmacokinetics in Critical Illness: A Systematic Review
Background An extracorporeal membrane oxygenation (ECMO) device represents an additional functional body compartment, potentially impacting vancomycin pharmacokinetics. Objectives This systematic review aimed to: (1) provide a comprehensive summary of vancomycin population pharmacokinetics (Pop-PK) in critically ill patients receiving ECMO and; (2) associate the findings with clinical practices and dosing recommendations. Methods PubMed, Embase and Google Scholar databases were searched for vancomycin non-linear mixed-effects modelling Pop-PK studies in ECMO patients (inception-May 2024). Standardized, pre-tested and pilot-tested tools were used for quality assessment and data extraction utilizing triangulation. Summary measures included typical values for vancomycin pharmacokinetic parameters, influential covariates, and associated interindividual and residual variabilities. Results Seven studies reporting an approximate total of 1600 vancomycin blood concentrations (range: 33–433 concentrations per study) collected from 215 patients (range: 11–93 patients per study) were included. Pop-PK models fitted three-compartment (n = 1), two-compartment (n = 5), or one-compartment (n = 1) models. Various modalities [venovenous-ECMO (n = 6); venoarterial-ECMO (n = 5), centrifugal-pump (n = 6), roller pump (n = 1)] and age groups were reported [pediatrics (n = 2); adults (n = 6)]. Vancomycin clearance and central volume of distribution (V1) ranged between 0.0579–4.32 L/h and 0.13–3.32L/kg, respectively. Relatively high between-subject variability (BSV) exists (clearance: 0.1%–77%; V1: 0.33%–94.8%). Models failed to explain maximally 19.4% of the overall variations, successfully explaining at least 80.6% of the variabilities in vancomycin disposition in ECMO. Age and body weight were significant covariates on clearance and V1. Additionally, glomerular filtration rate, serum creatinine, creatinine clearance, and use of dialysis were significant covariates on clearance. Clinical status-related covariates (i.e., acute physiology and chronic health evaluation II (APACHE-2) score, sequential organ failure assessment (SOFA) score, presence of shock) and ECMO modality-related covariates (pump type/flow rate, ECMO mode) were not significant covariates in the final clearance and V1 models. Conclusion This work comprehensively compiles up-to-date population-approach-based dosing simulations and pharmacokinetic models of vancomycin in ECMO, with special focus on influential predictors of vancomycin disposition to guide clinical dosing decisions. Relatively small sample sizes of patients were reported, a limitation that needs to be addressed in future large-scale studies. Observed BSV mandates therapeutic drug monitoring using Pop-PK models and parameters summarized in this work. Large-scale studies are needed to explore unexplored covariates, resulting in more informative dosing nomograms.
- 7 January 2025
- Published by Elsevier in Journal of Chromatography B
- Vol. 1252, 124449
Development and validation of a RP-HPLC method for simultaneous determination of cimetidine, metoprolol tartrate and phenol red for intestinal perfusion studies
- 7 January 2025
- Published by Elsevier in Journal of Chromatography B
- Vol. 1252, 124449
Development and validation of a RP-HPLC method for simultaneous determination of cimetidine, metoprolol tartrate and phenol red for intestinal perfusion studies
- 1 January 2025
- Published by Springer Nature
- p. 289-330
Electrospun Chitosan-Based Systems in Drug Delivery
- 1 January 2025
- Published by Springer Nature
- p. 289-330
Electrospun Chitosan-Based Systems in Drug Delivery